These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28222314)

  • 1. Systematic variation of the benzenesulfonamide part of the GluN2A selective NMDA receptor antagonist TCN-201.
    Müller SL; Schreiber JA; Schepmann D; Strutz-Seebohm N; Seebohm G; Wünsch B
    Eur J Med Chem; 2017 Mar; 129():124-134. PubMed ID: 28222314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic variation of the benzoylhydrazine moiety of the GluN2A selective NMDA receptor antagonist TCN-201.
    Schreiber JA; Müller SL; Westphälinger SE; Schepmann D; Strutz-Seebohm N; Seebohm G; Wünsch B
    Eur J Med Chem; 2018 Oct; 158():259-269. PubMed ID: 30218911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner.
    Edman S; McKay S; Macdonald LJ; Samadi M; Livesey MR; Hardingham GE; Wyllie DJ
    Neuropharmacology; 2012 Sep; 63(3):441-9. PubMed ID: 22579927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of GluN2A-selective NMDA receptor antagonists with an electron-rich aromatic B-ring.
    Rajan R; Schepmann D; Schreiber JA; Seebohm G; Wünsch B
    Eur J Med Chem; 2021 Jan; 209():112939. PubMed ID: 33162207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist.
    McKay S; Griffiths NH; Butters PA; Thubron EB; Hardingham GE; Wyllie DJ
    Br J Pharmacol; 2012 Jun; 166(3):924-37. PubMed ID: 22022974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [2.2]Paracyclophane-Based TCN-201 Analogs as GluN2A-Selective NMDA Receptor Antagonists.
    Rajan R; Schepmann D; Steigerwald R; Schreiber JA; El-Awaad E; Jose J; Seebohm G; Wünsch B
    ChemMedChem; 2021 Oct; 16(20):3201-3209. PubMed ID: 34265163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GluN2A-Selective NMDA Receptor Antagonists: Mimicking the U-Shaped Bioactive Conformation of TCN-201 by a [2.2]Paracyclophane System.
    Steigerwald R; Chou TH; Furukawa H; Wünsch B
    ChemMedChem; 2022 Nov; 17(21):e202200484. PubMed ID: 36169098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit.
    Volkmann RA; Fanger CM; Anderson DR; Sirivolu VR; Paschetto K; Gordon E; Virginio C; Gleyzes M; Buisson B; Steidl E; Mierau SB; Fagiolini M; Menniti FS
    PLoS One; 2016; 11(2):e0148129. PubMed ID: 26829109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of N-methyl-D-aspartate receptor-mediated excitatory postsynaptic potentials and synaptic plasticity to TCN 201 and TCN 213 in rat hippocampal slices.
    Izumi Y; Zorumski CF
    J Pharmacol Exp Ther; 2015 Feb; 352(2):267-73. PubMed ID: 25413830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human NMDA receptor GluN2A
    Marwick KFM; Skehel PA; Hardingham GE; Wyllie DJA
    Pharmacol Res Perspect; 2019 Aug; 7(4):e00495. PubMed ID: 31249692
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacology of triheteromeric N-Methyl-D-Aspartate Receptors.
    Cheriyan J; Balsara RD; Hansen KB; Castellino FJ
    Neurosci Lett; 2016 Mar; 617():240-6. PubMed ID: 26917100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinoxaline derivatives: structure-activity relationships and physiological implications of inhibition of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor-mediated currents and synaptic potentials.
    Randle JC; Guet T; Bobichon C; Moreau C; Curutchet P; Lambolez B; de Carvalho LP; Cordi A; Lepagnol JM
    Mol Pharmacol; 1992 Feb; 41(2):337-45. PubMed ID: 1371583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of the Mg2+-induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1/GluN2A NMDARs.
    Otton HJ; Lawson McLean A; Pannozzo MA; Davies CH; Wyllie DJ
    Neuropharmacology; 2011; 60(2-3):388-96. PubMed ID: 20955720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors.
    Mony L; Krzaczkowski L; Leonetti M; Le Goff A; Alarcon K; Neyton J; Bertrand HO; Acher F; Paoletti P
    Mol Pharmacol; 2009 Jan; 75(1):60-74. PubMed ID: 18923063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of rat recombinant GluN1/GluN2A and GluN1/GluN2B NMDA receptors by ethanol at concentrations based on the US/UK drink-drive limit.
    Otton HJ; Janssen A; O'Leary T; Chen PE; Wyllie DJ
    Eur J Pharmacol; 2009 Jul; 614(1-3):14-21. PubMed ID: 19394328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMDA receptors control vagal afferent excitability in the nucleus of the solitary tract.
    Vance KM; Rogers RC; Hermann GE
    Brain Res; 2015 Jan; 1595():84-91. PubMed ID: 25446446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action.
    Kleckner NW; Glazewski JC; Chen CC; Moscrip TD
    J Pharmacol Exp Ther; 1999 May; 289(2):886-94. PubMed ID: 10215667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors.
    Bettini E; Sava A; Griffante C; Carignani C; Buson A; Capelli AM; Negri M; Andreetta F; Senar-Sancho SA; Guiral L; Cardullo F
    J Pharmacol Exp Ther; 2010 Dec; 335(3):636-44. PubMed ID: 20810618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzyl-polyamines: novel, potent N-methyl-D-aspartate receptor antagonists.
    Igarashi K; Shirahata A; Pahk AJ; Kashiwagi K; Williams K
    J Pharmacol Exp Ther; 1997 Nov; 283(2):533-40. PubMed ID: 9353367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol.
    Ilyin VI; Whittemore ER; Guastella J; Weber E; Woodward RM
    Mol Pharmacol; 1996 Dec; 50(6):1541-50. PubMed ID: 8967976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.